[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE71599A1 - Inhibidores de proteasas - Google Patents

Inhibidores de proteasas

Info

Publication number
PE71599A1
PE71599A1 PE1998000336A PE00033698A PE71599A1 PE 71599 A1 PE71599 A1 PE 71599A1 PE 1998000336 A PE1998000336 A PE 1998000336A PE 00033698 A PE00033698 A PE 00033698A PE 71599 A1 PE71599 A1 PE 71599A1
Authority
PE
Peru
Prior art keywords
alkyl
alkyll
ccero
alkylll
amino
Prior art date
Application number
PE1998000336A
Other languages
English (en)
Inventor
Robert W Marquis
Daniel F Veber
Andrew D Gribble
Jason Witherington
Ashley Edward Fenwick
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE71599A1 publication Critical patent/PE71599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) O SU SAL, DONDE: R1 ES R", R"C(O), R"R`NC(O), ENTRE OTROS; R2 Y R4 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, Ar-ALQUILO Ccero-C6, Het-ALQUILO Ccero-C6; R3 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R6 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R' ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R" ES ALQUILO C1-C6, Ar-ALQUILO C CERO-C6, ENTRE OTROS; X ES O o S; n ES 1-3. SON COMPUESTOS PREFERIDOS 4-(R,S)-AMINO-N-[(3,4-METILENDIOXIBENZOIL)-S-LEUCINA]-TETRAHIDROFURAN-3-ONA, TRANS-4-(R,S)-AMINO-N-[BENCILOXICARBONIL)-S-LEUCINA]-3-HIDROXITETRAHIDROFURANO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO (I) INHIBE LA ENZIMA CISTEINA PROTEASA EN PARTICULAR LA CATEPSINA K, POR LO QUE PUEDE SER UTIL PARA INHIBIR PERDIDA OSEA, OSTEOPOROSIS, ENFERMEDAD GINGIVAL O PERIODONTAL; TRATAR UNA ENFERMEDAD CARACTERIZADA POR UNA DEGRADACION EXCESIVA DE CARTILAGO O MATRIZ COMO LA OSTEOARTRITIS O ARTRITIS REUMATOIDE
PE1998000336A 1997-05-06 1998-05-05 Inhibidores de proteasas PE71599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4575897P 1997-05-06 1997-05-06

Publications (1)

Publication Number Publication Date
PE71599A1 true PE71599A1 (es) 1999-09-15

Family

ID=21939723

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000336A PE71599A1 (es) 1997-05-06 1998-05-05 Inhibidores de proteasas

Country Status (19)

Country Link
EP (1) EP1003846A4 (es)
JP (1) JP2001525804A (es)
KR (1) KR20010012256A (es)
CN (1) CN1255161A (es)
AR (1) AR013079A1 (es)
AU (1) AU7562598A (es)
BR (1) BR9809306A (es)
CA (1) CA2288868A1 (es)
CO (1) CO4950618A1 (es)
HU (1) HUP0002247A3 (es)
IL (1) IL132088A0 (es)
NO (1) NO995434L (es)
NZ (1) NZ337889A (es)
PE (1) PE71599A1 (es)
PL (1) PL336856A1 (es)
TR (1) TR199902766T2 (es)
UY (1) UY25143A1 (es)
WO (1) WO1998050533A1 (es)
ZA (1) ZA983762B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
DZ3083A1 (fr) * 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
US6596715B1 (en) * 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
AU2001250570A1 (en) * 2000-10-19 2002-04-29 Naeja Pharmaceutical Inc, Dihydropyrimidine derivatives as cysteine protease inhibitors
ES2261341T3 (es) * 2000-11-17 2006-11-16 Medivir Ab Inhibidor de cisteina proteasa.
JP2004513942A (ja) * 2000-11-17 2004-05-13 メディヴァー　ユーケイ　リミテッド システインプロテアーゼインヒビター
NZ526912A (en) * 2001-01-17 2005-02-25 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
EP1362042A1 (en) * 2001-01-17 2003-11-19 Amura Therapeutics Limited Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
IL156774A0 (en) 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
US6841571B2 (en) * 2001-10-29 2005-01-11 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
AU2003255711B2 (en) * 2002-07-16 2008-11-13 Amura Therapeutics Limited Biologically active compounds
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
SG145745A1 (en) 2003-08-06 2008-09-29 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
AU2016206281B2 (en) * 2003-08-06 2017-11-30 Senomyx, Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
JP4787765B2 (ja) * 2004-01-08 2011-10-05 メディヴィル・アクチボラグ システインプロテアーゼ阻害剤
CN101287727A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力喹啉基激酶配体
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
AR067329A1 (es) * 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
GB0817424D0 (en) 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3190431B2 (ja) * 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
JPH05140063A (ja) * 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
IL121167A0 (en) * 1995-10-30 1997-11-20 Smithkline Beecham Corp Method of inhibiting cathepsin K
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
WO1998004539A1 (fr) * 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes

Also Published As

Publication number Publication date
NO995434D0 (no) 1999-11-05
BR9809306A (pt) 2000-07-04
EP1003846A1 (en) 2000-05-31
ZA983762B (en) 1998-11-06
NO995434L (no) 1999-11-05
CN1255161A (zh) 2000-05-31
IL132088A0 (en) 2001-03-19
AR013079A1 (es) 2000-12-13
UY25143A1 (es) 1998-11-27
CA2288868A1 (en) 1998-11-12
TR199902766T2 (xx) 2000-02-21
PL336856A1 (en) 2000-07-17
AU7562598A (en) 1998-11-27
HUP0002247A3 (en) 2003-01-28
EP1003846A4 (en) 2002-11-13
HUP0002247A2 (hu) 2001-05-28
KR20010012256A (ko) 2001-02-15
CO4950618A1 (es) 2000-09-01
NZ337889A (en) 2001-09-28
JP2001525804A (ja) 2001-12-11
WO1998050533A1 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
PE71599A1 (es) Inhibidores de proteasas
GEP19981488B (en) Dihalotriazolopyrimidine Derivatives,Method for Its Production, Fungicidal Composition on Its Basis and Their Use as Fungicides
PE73799A1 (es) Inhibidores de proteasas
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
BR9801743A (pt) Composição microbicida estável e processo para evitar a formação de precipitado em uma composição microbicida e para controlar ou inibir o crescimento de microorganismos em um local.
ATE226193T1 (de) Substituierte zyklische amine als metalloproteaseinhibitoren
NO302474B1 (no) Sakarinderivater, farmasöytisk sammensetning og anvendelse derav
TR200003752T2 (tr) Sinerjik etkili herbisit karışımlar
PE64398A1 (es) Derivados de azetidinona
AR012531A1 (es) Composicion para cuidado personal, composicion para repasador y metodo para minimizar o reducir la comezon o quemado de la piel a causa de composicionespara cuidado personal que contienen acido.
NO996269L (no) Kinolin-indol antimikrobielle midler, samt anvendelse og blandinger derav
ATE411294T1 (de) 4-amino-azepan-3-on-derivate als protease- inhibitors
EP0513387A4 (en) Active oxygen inhibitor
PL311641A1 (en) Fungicidal conjugated bicyclic pyrimidones
MX9305470A (es) Metodo para incrementar la eficacia de una composicion de limpieza desinfectante.
DE69232929D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
PL328412A1 (en) Derivatives of benzamidine substituted with derivatives of amino acid and hydroxy acid as well as their application as antithrombotic agents
PE20050483A1 (es) Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
MX9305567A (es) Imidas biciclicas.
BR9801714A (pt) Composição microbicida estável e processo para estabilizar uma composição microbicida e para controlar ou inibir o crescimento de microorganismos em um local.
AR005532A1 (es) Compuestos de dihalopropeno, las composiciones insecticidas/acaricidas que los contienen y los intermediarios de sintesis de dichos compuestos
PT1089625E (pt) Agentes ectoparasiticidas
ES2132383T3 (es) Inhibidores de proteasa hiv.
PE20011374A1 (es) 4-amino-azepan-3-ona como inhibidores de proteasas

Legal Events

Date Code Title Description
FD Application declared void or lapsed